| Application number | Title of the application | Filing Date | Status |
|---|
Array
(
[id] => 19125801
[patent_doc_number] => 20240131154
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-25
[patent_title] => COMBINATION OF NOVEL VACCINES AGAINST ZIKA VIRUS AND DNA ANTIBODY CONSTRUCTS FOR USE AGAINST ZIKA VIRUS
[patent_app_type] => utility
[patent_app_number] => 18/477785
[patent_app_country] => US
[patent_app_date] => 2023-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40405
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18477785
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/477785 | COMBINATION OF NOVEL VACCINES AGAINST ZIKA VIRUS AND DNA ANTIBODY CONSTRUCTS FOR USE AGAINST ZIKA VIRUS | Sep 28, 2023 | Pending |
Array
(
[id] => 19125801
[patent_doc_number] => 20240131154
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-25
[patent_title] => COMBINATION OF NOVEL VACCINES AGAINST ZIKA VIRUS AND DNA ANTIBODY CONSTRUCTS FOR USE AGAINST ZIKA VIRUS
[patent_app_type] => utility
[patent_app_number] => 18/477785
[patent_app_country] => US
[patent_app_date] => 2023-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40405
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18477785
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/477785 | COMBINATION OF NOVEL VACCINES AGAINST ZIKA VIRUS AND DNA ANTIBODY CONSTRUCTS FOR USE AGAINST ZIKA VIRUS | Sep 27, 2023 | Pending |
Array
(
[id] => 18970473
[patent_doc_number] => 20240050565
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-15
[patent_title] => ANTIBODIES THAT POTENTLY NEUTRALIZE RABIES VIRUS AND OTHER LYSSAVIRUSES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/454011
[patent_app_country] => US
[patent_app_date] => 2023-08-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46602
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18454011
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/454011 | ANTIBODIES THAT POTENTLY NEUTRALIZE RABIES VIRUS AND OTHER LYSSAVIRUSES AND USES THEREOF | Aug 21, 2023 | Abandoned |
Array
(
[id] => 19127225
[patent_doc_number] => 20240132578
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-25
[patent_title] => METHODS OF TREATING HIV-1 INFECTION UTILIZING BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/452002
[patent_app_country] => US
[patent_app_date] => 2023-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 97627
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18452002
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/452002 | Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies | Aug 17, 2023 | Issued |
Array
(
[id] => 19127225
[patent_doc_number] => 20240132578
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-25
[patent_title] => METHODS OF TREATING HIV-1 INFECTION UTILIZING BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/452002
[patent_app_country] => US
[patent_app_date] => 2023-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 97627
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18452002
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/452002 | Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies | Aug 17, 2023 | Issued |
Array
(
[id] => 19034139
[patent_doc_number] => 20240083954
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => COMPOSITIONS AND METHODS RELATED TO HIV-1 IMMUNOGENS
[patent_app_type] => utility
[patent_app_number] => 18/449739
[patent_app_country] => US
[patent_app_date] => 2023-08-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23266
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18449739
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/449739 | COMPOSITIONS AND METHODS RELATED TO HIV-1 IMMUNOGENS | Aug 14, 2023 | Abandoned |
Array
(
[id] => 18903060
[patent_doc_number] => 20240018545
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-18
[patent_title] => ADENO-ASSOCIATED VIRUS (AAV) PRODUCER CELL LINE AND RELATED METHODS
[patent_app_type] => utility
[patent_app_number] => 18/352657
[patent_app_country] => US
[patent_app_date] => 2023-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18769
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18352657
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/352657 | ADENO-ASSOCIATED VIRUS (AAV) PRODUCER CELL LINE AND RELATED METHODS | Jul 13, 2023 | Pending |
Array
(
[id] => 18786089
[patent_doc_number] => 20230374078
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-23
[patent_title] => Trimer Stabilizing HIV Envelope Protein Mutations
[patent_app_type] => utility
[patent_app_number] => 18/342949
[patent_app_country] => US
[patent_app_date] => 2023-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31839
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18342949
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/342949 | Trimer Stabilizing HIV Envelope Protein Mutations | Jun 27, 2023 | Abandoned |
Array
(
[id] => 19035604
[patent_doc_number] => 20240085419
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => METHODS AND KITS FOR QUANTIFYING THE REMOVAL OF MOCK VIRUS PARTICLES FROM A PURIFIED SOLUTION
[patent_app_type] => utility
[patent_app_number] => 18/212606
[patent_app_country] => US
[patent_app_date] => 2023-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12148
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18212606
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/212606 | METHODS AND KITS FOR QUANTIFYING THE REMOVAL OF MOCK VIRUS PARTICLES FROM A PURIFIED SOLUTION | Jun 20, 2023 | Pending |
Array
(
[id] => 19909293
[patent_doc_number] => 12285481
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-29
[patent_title] => Methods for the treatment of COVID-19 comprising administering replication-defective adenoviruses encoding the SARS-CoV-2 spike glycoprotein and modified nucleocapsid protein
[patent_app_type] => utility
[patent_app_number] => 18/312532
[patent_app_country] => US
[patent_app_date] => 2023-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 7
[patent_no_of_words] => 3444
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 98
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312532
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/312532 | Methods for the treatment of COVID-19 comprising administering replication-defective adenoviruses encoding the SARS-CoV-2 spike glycoprotein and modified nucleocapsid protein | May 3, 2023 | Issued |
Array
(
[id] => 18725813
[patent_doc_number] => 20230340033
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => Immunogenic Compositions Against SARS-COV-2 Variants And Their Methods Of Use
[patent_app_type] => utility
[patent_app_number] => 18/300973
[patent_app_country] => US
[patent_app_date] => 2023-04-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21354
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18300973
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/300973 | Immunogenic Compositions Against SARS-COV-2 Variants And Their Methods Of Use | Apr 13, 2023 | Pending |
Array
(
[id] => 19969685
[patent_doc_number] => 12338277
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-24
[patent_title] => Broadly neutralizing antibodies that target HIV ENV V3 N-glycans
[patent_app_type] => utility
[patent_app_number] => 18/297301
[patent_app_country] => US
[patent_app_date] => 2023-04-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 27
[patent_no_of_words] => 27062
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18297301
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/297301 | Broadly neutralizing antibodies that target HIV ENV V3 N-glycans | Apr 6, 2023 | Issued |
Array
(
[id] => 18831181
[patent_doc_number] => 20230399707
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-14
[patent_title] => Methods, Compositions and Systems for Respiratory Virus Detection
[patent_app_type] => utility
[patent_app_number] => 18/131262
[patent_app_country] => US
[patent_app_date] => 2023-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19461
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18131262
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/131262 | Methods, Compositions and Systems for Respiratory Virus Detection | Apr 4, 2023 | Pending |
Array
(
[id] => 18553244
[patent_doc_number] => 20230251256
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => MOLECULES, AND RELATED ASSAYS, TEST KITS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 18/296328
[patent_app_country] => US
[patent_app_date] => 2023-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26552
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18296328
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/296328 | MOLECULES, AND RELATED ASSAYS, TEST KITS AND METHODS | Apr 4, 2023 | Pending |
Array
(
[id] => 18553244
[patent_doc_number] => 20230251256
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => MOLECULES, AND RELATED ASSAYS, TEST KITS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 18/296328
[patent_app_country] => US
[patent_app_date] => 2023-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26552
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18296328
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/296328 | MOLECULES, AND RELATED ASSAYS, TEST KITS AND METHODS | Apr 4, 2023 | Pending |
| 18/005332 | COVID-19 Mucosal Antibody Assay | Jan 11, 2023 | Pending |
| 18/005332 | COVID-19 Mucosal Antibody Assay | Jan 11, 2023 | Pending |
Array
(
[id] => 19930367
[patent_doc_number] => 12303560
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-20
[patent_title] => Recombinant bovine immunodeficiency virus-like particles comprising an influenza HA transmembrane domain and C-terminus
[patent_app_type] => utility
[patent_app_number] => 18/153667
[patent_app_country] => US
[patent_app_date] => 2023-01-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 41
[patent_no_of_words] => 16077
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18153667
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/153667 | Recombinant bovine immunodeficiency virus-like particles comprising an influenza HA transmembrane domain and C-terminus | Jan 11, 2023 | Issued |
Array
(
[id] => 19362125
[patent_doc_number] => 20240264159
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => SYSTEM, METHOD AND KITS FOR THE DETECTION OF BINDING AGENTS
[patent_app_type] => utility
[patent_app_number] => 18/564895
[patent_app_country] => US
[patent_app_date] => 2022-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11090
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18564895
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/564895 | SYSTEM, METHOD AND KITS FOR THE DETECTION OF BINDING AGENTS | Dec 22, 2022 | Pending |
Array
(
[id] => 18389916
[patent_doc_number] => 20230158134
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => CHIMPANZEE ADENOVIRUS CONSTRUCTS WITH LYSSAVIRUS ANTIGENS
[patent_app_type] => utility
[patent_app_number] => 18/075064
[patent_app_country] => US
[patent_app_date] => 2022-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22320
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 251
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18075064
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/075064 | CHIMPANZEE ADENOVIRUS CONSTRUCTS WITH LYSSAVIRUS ANTIGENS | Dec 4, 2022 | Abandoned |